MannKind Corporation

Inhaled therapeutics

MNKD · Nasdaq · United States

Share price · MNKD

$4.07+0.00 (+0.00%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.3M (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MNKD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026+4.3%

    Nothing announced by MNKD that day or the session before.

  2. 30 Sep 2026+16.8%
  3. 2 Jul 2026+11.6%

    Nothing announced by MNKD that day or the session before.

  4. 6 May 2026+24.5%
  5. 25 Feb 2026-36.8%
  6. 16 Jan 2026-6.6%

    Nothing announced by MNKD that day or the session before.

Share of unusual movement by asset

For each asset, the share of MNKD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)
events and moves
3shown from 8 days
Afrezza (Afrezza)
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—21%
Sessions with no dated event—77%

Assets

(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
7Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
InsulinPeptide
Type 2 DiabetesType 1 Diabetes
Approved
NKCC2Small molecule
Heart FailureChronic Kidney Disease
Approved
IP receptor (prostacyclin pathway)Small molecule
Idiopathic Pulmonary FibrosisPulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
AfrezzaPhase 2Type 1 Diabetes Mellitus
Est. primary completion 2027-03 · NCT07224321 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 July 2026Topline resultMNKD-201Phase 1b INFLO-1 topline results for nintedanib DPI in IPF
24 July 2026ApprovalFurosemide (subcutaneous, scPharmaceuticals)FDA approves Furoscix ReadyFlow autoinjector for edema in HF and CKD
US, FDA · Source ↗
29 May 2026ApprovalAfrezzaFDA approves Afrezza for pediatric use (ages 6+)
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$102M$14M$41M+ $55M short-term inv.$23M-$35M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$109M$18M$53M+ $58M short-term inv.$19M-$18M operating cash flowreport ↗
2026-Q1$90M$17M$53M+ $81M short-term inv.$17M-$5.4M operating cash flowreport ↗
2025-Q3$82M$14M$127M+ $133M short-term inv.—$24M operating cash flowreport ↗
2025-Q2$77M$14M$57M+ $122M short-term inv.—$8.9M operating cash flowreport ↗
2025-Q1$78M$11M$47M+ $134M short-term inv.—-$6.4M operating cash flowreport ↗
2024-Q3$70M$13M$62M+ $189M short-term inv.—$9.3M operating cash flowreport ↗
2024-Q2$72M$12M$97M+ $151M short-term inv.$2.0M$3.8M operating cash flowreport ↗
2024-Q1$66M$10M$193M+ $107M short-term inv.—$6.7M operating cash flowreport ↗
2023-Q3$51M$10.0M$83M+ $58M short-term inv.—$8.7M operating cash flowreport ↗
2023-Q2$49M$6.5M$86M+ $58M short-term inv.$5.3M$2.6M operating cash flowreport ↗
2023-Q1$41M$5.6M$86M+ $80M short-term inv.$9.8M$1.2M operating cash flowreport ↗
2022-Q3$33M$4.1M$54M+ $111M short-term inv.$14M-$28M operating cash flowreport ↗
2022-Q2$19M$4.9M$36M+ $119M short-term inv.$29M-$32M operating cash flowreport ↗
2022-Q1$12M$3.5M$67M+ $95M short-term inv.$26M-$18M operating cash flowreport ↗
2021-Q3$22M$3.7M$52M+ $87M short-term inv.$4.4M-$15M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$349M$66M$75M+ $96M short-term inv.—$18M operating cash flowreport ↗

MannKind reported full-year 2025 revenue of $348.97M, up 22.2% YoY, with R&D spend of $66.35M, up 44.6% YoY. Cash and equivalents were $74.88M at year-end, and total cash, equivalents and investments were $176M. The company reported net income of $5.86M for the year.

During the period, MannKind completed its acquisition of scPharmaceuticals, adding Furoscix, which generated Q4 2025 net sales of $23M, up 91% YoY, while Afrezza Q4 net sales were $23M, up 25% YoY. Regulatory milestones include FDA acceptance of the Afrezza pediatric sBLA with a PDUFA date of May 29, 2026, and the Furoscix ReadyFlow Autoinjector sNDA with a PDUFA date of July 26, 2026. Enrollment is underway in the Nintedanib DPI Phase 1b INFLO-1 study with topline data expected in 2H 2026, and a Phase 2 trial in IPF is planned to enroll its first patient in Q2 2026. Other updates include preclinical development of Bumetanide DPI, formulation work on MNKD-1501 under the United Therapeutics collaboration, and Afrezza’s launch in India by Cipla.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$286M$46M$46M+ $151M short-term inv.—$43M operating cash flowreport ↗
2023-FY$199M$31M$238M+ $57M short-term inv.$3.0M$34M operating cash flowreport ↗
2022-FY$100M$20M$70M+ $101M short-term inv.$22M-$81M operating cash flowreport ↗
2021-FY$75M$12M$124M+ $80M short-term inv.$20M-$62M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($259K), 13 sales ($3.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Friedman Michael A · directorOption exercise30,000$1.10$33KForm 4
2026-11-17Friedman Michael A · directorTax withholding8,109$4.07$33KForm 4
2026-11-17Friedman Michael A · directorOption exercise (derivative)30,000——Form 4
2026-09-25Binder Steven B. · directorOpen-market sale39,051$3.29$128KForm 4
2026-09-10Binder Steven B. · directorOpen-market sale33,558$3.81$128KForm 4
2026-08-07Binder Steven B. · directorOpen-market sale39,051$4.06$159KForm 4
2026-07-17Binder Steven B. · directorOpen-market sale52,485$4.06$213KForm 4
2026-07-17Thomson David · EVP Genl Counsel & SecretaryOpen-market sale24,109$4.05$98KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 249 reporting institutions held 176.7M shares ($431.3M, 54.9% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.28,600,998$70.1M
2STATE STREET CORP18,683,483$45.8M
3VANGUARD CAPITAL MANAGEMENT LLC12,891,066$31.6M
4UBS Group AG8,255,430$20.2M
5GEODE CAPITAL MANAGEMENT, LLC7,505,147$18.4M
6MILLENNIUM MANAGEMENT LLC6,390,922$15.7M
7Frazier Life Sciences Management, L.P.5,900,000$14.5M
8MORGAN STANLEY5,793,147$14.2M
9DIMENSIONAL FUND ADVISORS LP4,953,295$12.1M
10180 WEALTH ADVISORS, LLC4,291,703$10.5M
11Rubric Capital Management LP3,620,413$8.9M
12FMR LLC3,480,964$8.5M
13BANK OF AMERICA CORP /DE/3,383,677$8.3M
14WELLINGTON MANAGEMENT GROUP LLP3,283,179$8.0M
15VANGUARD PORTFOLIO MANAGEMENT LLC3,171,824$7.8M